Peptides Codex
ENFR
← Home
Dual GLP-1 / glucagon receptor agonist (oxyntomodulin analog)

Mazdutide

Mazdutide (IBI362, LY3305677) is a dual GLP-1 and glucagon receptor agonist derived from oxyntomodulin. It has been studied in metabolic research and is approved in China, while remaining unauthorized in Canada. This page is educational and not medical advice.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Dual GLP-1 / glucagon receptor agonist (oxyntomodulin analog)
Function
Studied as an oxyntomodulin-based incretin co-agonist
Context
Investigational in most markets; not authorized by Health Canada

An oxyntomodulin-based dual agonist central to next-generation metabolic peptide science.

Also known as: IBI362 · LY3305677

Part of the Metabolic & GLP-1 peptides cluster

Overview

Mazdutide (IBI362, LY3305677) is a dual GLP-1 and glucagon receptor agonist derived from oxyntomodulin. It has been studied in metabolic research and is approved in China, while remaining unauthorized in Canada. This page is educational and not medical advice.

Source & context

Biological / chemical source: Synthetic peptide analog of oxyntomodulin (Eli Lilly / Innovent Biologics)

Primary research or clinical context: Investigational in most markets; not authorized by Health Canada

Oxyntomodulin backbone

Mazdutide is described as an analog of oxyntomodulin, a naturally occurring gut peptide that itself activates both GLP-1 and glucagon receptors. Engineering that native dual activity into a long-acting molecule is the core scientific idea behind the compound. Exact sequence and acylation specifics are proprietary.

Development and comparisons

Developed by Eli Lilly and Innovent Biologics, mazdutide is frequently compared with survodutide, tirzepatide, and retatrutide in discussions of dual- versus triple-agonist strategies. Regulatory status differs by country; approval in one market does not imply authorization in Canada.

Educational framing

Search interest in mazdutide is high because of the broader metabolic-peptide trend. Readers should distinguish region-specific approvals from Canadian status and rely on primary trial data rather than marketing summaries. No dosing or treatment guidance is provided here.

FAQ about Mazdutide

What is Mazdutide?+

Mazdutide (IBI362, LY3305677) is a dual GLP-1 and glucagon receptor agonist derived from oxyntomodulin. It has been studied in metabolic research and is approved in China, while remaining unauthorized in Canada. This page is educational and not medical advice.

Is Mazdutide an approved medicine?+

Mazdutide is discussed here as a research / educational topic. Investigational in most markets; not authorized by Health Canada. This is not medical advice.

What is the typical length of Mazdutide?+

Mazdutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

Cerebrolysin
Enzymatically processed neuropeptide mixture
Cerebrolysin is an experimental mixture of low-molecular-weight peptides and amino acids produced by enzymatic breakdown of purified pig brain protein. It is studied for neurotrophic effects and used by prescription in some countries, but is not approved in Canada or the United States.
BPC-157
Research peptide
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide studied in preclinical models of tissue repair and gastrointestinal protection. It is not an approved therapeutic in Canada or the United States.
TB-500
Research peptide
TB-500 refers to a synthetic peptide fragment associated with thymosin beta-4 research, studied for effects on cell migration and tissue remodeling in experimental models. It is not an approved medicine.
Tirzepatide
Incretin dual agonist
Tirzepatide is an engineered dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist peptide. It is an approved prescription medicine in multiple jurisdictions and a major case study in multi-receptor peptide design.

References & further reading

  1. 1.Wikipedia — Mazdutide
  2. 2.PubChem — compound summary for Mazdutide (CID 167312357)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Mazdutide educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.